Celgene Corp (CELG.O) News| Reuters.com
Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

96.29USD
24 Jun 2016
Change (% chg)

$-4.37 (-4.34%)
Prev Close
$100.66
Open
$97.20
Day's High
$98.65
Day's Low
$96.26
Volume
7,136,674
Avg. Vol
4,733,967
52-wk High
$140.72
52-wk Low
$92.98

Select another date:

Wed, Jun 15 2016

BRIEF-Celgene announces additional $3 bln share repurchase authorization

* Celgene announces additional $3 billion share repurchase authorization

BRIEF-Bionor Pharma says possible extension of alliance with Celgene

* Says scientific collaborations include possible extension of ongoing collaboration with Celgene Corporation Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels

* Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association

BRIEF-Bionor Pharma: Updated clinical strategy, reduced capital needs

* Says maintains its focus on HIV immunotherapy and overall strategy to further advance VACC-4x in clinical development in combination with other medicines

BRIEF-Agios Pharmaceuticals, Celgene establish new collaboration in metabolic immuno-oncology

* Agios and Celgene establish new collaboration in metabolic immuno-oncology and amend certain rights from 2010 agreement

BRIEF-Triphase expands current collaboration with Celgene in development of marizomib

* Expanding current collaboration with Celgene Corp in development of marizomib for potential treatment of malignant gliomasb Source text for Eikon: Further company coverage:

Celgene revenue rises less than expected due to strong dollar

U.S. biotechnology company Celgene Corp reported first-quarter revenue that fell just shy of analysts estimates due to the stronger dollar, sending the company's shares down 1.5 percent in premarket trading.

BRIEF-Celgene reports Q1 earnings $0.99/shr

* Celgene reports first quarter 2016 operating and financial results

Celgene revenue rises about 21 pct

April 28 U.S. biotechnology company Celgene Corp reported a 20.7 percent rise in quarterly revenue, helped by higher demand for its flagship multiple myeloma drug, Revlimid.

BRIEF-Agios, Celgene Corp to defer selection process for allocating rights to certain discovery programs

* Co and Celgene Corp agreed to defer from April 14, 2016 to June 1, 2016 selection process for allocating rights to certain discovery programs

Select another date: